About

1986

The first Lifecare AS was established, with the purpose to develop a patented artificial pancreas.

1998

Lifecare’s development was shifted to focus on development of implantable sensor to measure and monitor the glucose level by osmotic pressure, based on the original invention of Olav Ellingsen. Conceptual focus on development of membrane for exclusion of glucose as base for measuring of variations of osmolarity within a cell, referred to as an “osmotic membrane”.

1999

• Approved patent: “Method for monitoring the level of an osmotically active component in body fluid and device for carrying out said method”.
• R&D cooperation established with SINTEF, Trondheim, Norway.

2002

Pre-clinical studies of sensor for measurements and monitoring of the glucose with osmotic membrane, in cooperation with SINTEF and St. Olavs Hospital in Trondheim, Norway.

2005

R&D cooperations with the University of Glasgow / Kelvin Nanotechnologies Ltd and Centre Swiss for Electronics and Microtechnology (CSEM).

2006

Strategic restructuring led to the incorporation of todays Lifecare, with the purpose to develop the glucose sensor Sencell.

2007

Feasibility study on use of fluid reactive to glucose to induce osmolarity changes – establishment of the concept of an osmotic sensor.

2009-2012

Industrial research project at Vestfold University College (Department of Micro- and Nanosystems Technology), Norway, supervised by Associate Professor Erik Johannessen, Professor Henrik Jacobsen, and Professor Tor Inge Tønnessen, leading to the Doctoral Thesis “Osmotic sensor for blood glucose monitoring applications” by Olga Krushinitskaya (Ph.D).

2011

Approved patent: Apparatus and method for measuring augmented osmotic pressure in a reference cavity.

2014

Lifecare engaged Prof. Dr. Dr. Andreas Pfützner as consultant CSO, being a medical doctor and globally recognized expert in the development of medical devices in diabetes technology.

2015-2016

Lifecare carried out pre-clinical studies of the sensor in pigs.

2017

Lifecare entered a Product Development Agreement with Sanofi, ensuring milestone-based funding contributions, in return of a right of first refusal to negotiate allowing an exclusive opportunity to license the Sencell technology.

2018

Lifecare was listed on Euronext Growth.

2021

• Lifecare acquired CantiMed UG and restructured the company to Lifecare NanoBioSensors GmbH.
• Approved patent: Interstitial fluid osmotic pressure measuring device system and method.

2022

• Lifecare acquired the laboratory of Pfützner Science & Health Institute GmbH and incorporated the entity as Lifecare Laboratory GmbH.
• Successful, high quality in-vitro test results with the miniaturized Sencell.
• Lifecare innovations categorized by European Commission’s Innovation Radar as “Market Ready” and among top 14% of innovations in scientific projects receiving financial grants from the European Commission.
• Successful private placement raising gross proceeds of NOK 45 million.
• Incorporation of Lifecare Chemistry Ltd.

2023

• Finalization of clinical development study confirming accurate sensor performance in humans.
• Incorporation of Lifecare Veterinary AS.
• Successful private placement raising gross proceeds of NOK 42.5 million.
• The Norwegian Food Safety Authority awarded all necessary approvals to start working on the second Sencell clinical study.

2024

• Approved patent: Fluid composition, method for preparing the composition and use.
• Established pilot production of the Sencell sensor, paving the way for automated production.
• Acquisition of 89.6% in RemovAid.
• Successful rights issues raising gross proceeds of NOK 106 million.
• Strategic partnership with OneTwo Analytics to make glucose data from the sensor accessible.
• Longevity trial in dog confirming sensor performance.
• Listed on Euronext Oslo Børs.